<DOC>
	<DOCNO>NCT01830868</DOCNO>
	<brief_summary>This Non-interventional Prospective Study . Centres enroll adult patient partial onset seizure clinician decide initiate ZNS adjunctive therapy prior decision take part study . Patients enrol study sufficiently control one dug license use monotherapy partial onset seizure . Patients see baseline normal clinical visit interval appropriate typical practice treat clinician . Patients assessed baseline least 3 6 month baseline .</brief_summary>
	<brief_title>A Post-marketing Observational Study Of The Use Of Zonisamide ( ZNS ) Adjunctive Treatment Of Adult Patients With Partial Onset Seizures ( Study E2090-E044-410 )</brief_title>
	<detailed_description>Open-label , Multi-centre , Multi-national Post-marketing , Non-interventional Observational Study</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>The decision prescribe ZNS make physician independently his/her decision include patient study Patients treat one drug license use monotherapy partial onset seizure Based physician 's clinical judgment , patient seizure activity control sufficiently current monotherapy patient 's best interest prescribe adjunctive ZNS Patient prescribe ZNS longer 2 week baseline Treatment ZNS commence line drug 's license ZNS SmPC ( Summary Product Characteristics ) Aged 18 year older Capable understand purpose study , fully inform give write informed consent . Patients start ZNS outside approve SmPC enrolment Simultaneous participation interventional clinical trial and/or take investigational drug Any form substance abuse , psychiatric disorder condition , opinion investigator , may complicate communication patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>ZNS</keyword>
	<keyword>AED</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Retention Rate</keyword>
	<keyword>Seizure Control</keyword>
	<keyword>Antiepileptic</keyword>
	<keyword>Secondary generalization</keyword>
	<keyword>Seizure freedom rate</keyword>
</DOC>